Affecting roughly 5,000 people in the U.S., C3 glomerulopathy and immune-complex MPGN are two rare glomerulopathies ...

Janux Therapeutics' cash runway is about 12 months; dilution is likely, and upcoming data from both JANX007 and JANX008 are ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful ...

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no ...

A surprising link between constipation and kidney decline led researchers to test lubiprostone, revealing that it can protect ...

Surviving longer and remaining healthier in later life is influenced by many factors beyond classical blood lipids. A growing ...

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, largely due to metastasis and therapeutic ...

FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 4:00 PM ESTCompany ParticipantsMarshall Fordyce - ...

Following its latest earnings and regulatory guidance, Sangamo Therapeutics has seen its fair value estimate hold steady at $3.25 per share, while its discount rate ticked up marginally from 7.28% to ...

Otsuka receives US FDA accelerated approval for Voyxact to reduce proteinuria in adults with IgAN: Princeton, New Jersey Thursday, November 27, 2025, 12:00 Hrs [IST] Otsuka Pharma ...

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...